αβ T lymphocytes are critical for host protection against pathogens and are notable for their recent use as immunotherapeutic agents for the treatment of human cancer. However, their dysfunction is associated with a variety of disease states, including autoimmune and immunodeficient syndromes that frequently result from improper αβ T cell development in the thymus. After thymic egress, mature αβ T cells are activated when their surface T-cell receptor (TCR) engages peptide antigens displayed by major histocompatibility complex (MHC) proteins expressed on antigenpresenting cells. In the thymus, each developing αβ T cell (thymocyte) recombines its TCRβ and TCRα genes in an attempt to assemble and express a unique functional αβ TCR, which is required for survival and development into CD4 + CD8 + double-positive (DP) thymocytes. The affinity of the TCR for peptide:MHC displayed by thymic epithelial cells dictates whether the immature αβ T lymphocyte survives and continues differentiating (low affinity directs positive selection) or dies via apoptosis (high affinity triggers negative selection). Altogether, these two checkpoints ensure that the host generates a diverse protective and self-tolerant αβ TCR repertoire. Although it is recognized that the degree and extent of TCR signaling activated by intra-thymic TCR/peptide: MHC interactions directs positive or negative selection, the precise intracellular mechanisms that orchestrate this developmental decision remain enigmatic. In this research highlight, we discuss recent work from Adoro et al. 1 that uncovers an unexpected and essential function of the ESCRT (Endosomal Sorting Complex Required for Transport) protein CHMP5 in mediating thymocyte positive selection.
Prior studies had indicated roles for proteasome-dependent post-translational regulatory mechanisms in TCR signaling and in αβ T cell development. [2] [3] [4] Adoro et al. 1 sought to identify proteins for which the expression in thymocytes is regulated by proteasomal degradation. They found that the CHMP5 protein was stabilized upon treatment with an ubiquitin-dependent proteasome inhibitor. By quantifying Chmp5 transcription and CHMP5 protein levels in thymocytes at specific developmental stages, they discovered that CHMP5 is posttranscriptionally regulated, with the highest CHMP5 protein levels found in post-positively selected thymocytes. As germline CHMP5-deficient mice exhibit early embryonic lethality, 5 Adoro et al. 1 generated and analyzed mice with an αβ T lineage-specific deletion of Chmp5 initiating in DP thymocytes prior to positive selection. These mice exhibited lower frequencies and numbers of positively selected thymocytes, disorganized thymic architecture with fragmented medullary regions, and reduced frequencies and numbers of mature αβ T cells. The few αβ T cells that did develop in these mice retained CHMP5 protein expression due to incomplete gene deletion. Using mixed bone marrow chimeric mice, the authors determined that the defect in αβ T cell development is caused by loss of thymocyte-intrinsic CHMP5 function. These observations reveal an essential role (or roles) for CHMP5 in αβ T-cell differentiation at the developmental transition associated with positive selection.
CHMP5 has non-redundant functions in membrane distortion/scission events, such as the formation of lysosomes, and in the control of protein ubiquitylation. In mouse embryos, the loss of CHMP5 protein inhibits lysosomal degradation of activated receptors, thereby increasing signal transduction. 5 However, in mouse osteoclasts, CHMP5 suppresses ubiquitylation of the IκBα protein and thereby down-regulates the activity of NFκB transcription factors, without any discernable effect on lysosomal biogenesis or receptor dynamics. 6 Adoro et al. 1 found normal expression, endocytosis, and trafficking of TCR proteins in CHMP5-inactivated DP thymocytes. They also detected normal phosphorylation and activation of TCR signaling molecules, and minimal perturbations in NFκB activity or transcriptomes, in Chmp5-deficient DP thymocytes. Notably, inactivation of CHMP5 had no effect on the ability of TCR signaling to induce gene transcript changes associated with positive selection. These data are consistent with a role for CHMP5 in the posttranscriptional regulation of the genetic program that drives positive selection of immature αβ T cells.
As impaired positive selection is usually due to defects in TCR signaling or cellular survival, 7-10 Adoro et al. 1 investigated whether CHMP5 promotes the survival of positively selected thymocytes through post-transcriptional mechanisms. Indeed, they found increased apoptosis of post-positively selected cells that correlated with decreased levels of the anti-apoptotic Bcl2 protein despite normal expression of Bcl2 transcripts. They also discovered that CHMP5 physically interacts with Bcl2 and that degradation of Bcl2 protein is triggered by reactive oxygen species (ROS)-mediated oxidation. 11, 12 The Bcl2 protein in CHMP5-deficient thymocytes was highly oxidized, more so than normal, suggesting that CHMP5 suppresses Bcl2 degradation to promote the survival of post-selected thymocytes. Consistent with this notion, transgenic Bcl2 overexpression enhanced the positive selection of CHMP5-deficient thymocytes as evidenced by partial restoration of αβ T cell development. Thus, Adoro et al. 1 propose that CHMP5-mediated posttranslational stabilization of Bcl2 enables the survival of positively selected thymocytes and thereby promotes the efficient generation of αβ T cells during positive selection.
The authors next investigated the potential regulation of CHMP5 protein expression during thymocyte selection. They elucidated that treatment with low doses of TCR agonists or low-affinity peptides increased CHMP5 protein levels without affecting Chmp5 mRNA levels, whereas high doses of TCR agonists or high-affinity peptides decreased the expression of Chmp5 mRNA and CHMP5 protein levels. This latter response correlated with an increased ubiquitylation of CHMP5 protein. Mass spectrometry of CHMP5 from cells treated with a low dose of TCR agonist revealed phosphorylation at serine 20 and serine 30, as well as ubiquitylation at lysine 100. Subsequent substitution of lysine 100 with arginine, which cannot be ubiquitylated, increased the stability of CHMP5 protein. Conversely, replacement of serine 20 and serine 30 with glycine and alanine, which cannot be phosphorylated, led to constitutive ubiquitylation of lysine 100. These data suggest that low-affinity TCR peptides increase CHMP5 protein levels by inducing phosphorylation at serine 20 and serine 30, which antagonizes the ubiquitylation of lysine 100 and consequent proteasomal-mediated degradation. Adoro et al. 1 hypothesized that TCRsignaled stabilization of CHMP5 may involve the activation of a specific deubiquitinase (DUB) protein. Indeed, they found that over-expression of the USP8 DUB enzyme reduced ubiquitylation of CHMP5. Moreover, low doses of TCR agonists upregulated thymocyte expression of USP8, leading to an interaction between USP8 and CHMP5 proteins. The substitution of CHMP5 serine 20 and serine 30 with glycine and alanine blocked this interaction, suggesting that TCR-signaled CHMP5 phosphorylation stabilized CHMP5, at least in part, by promoting its association with USP8. Consistent with this notion, USP8-inactivated thymocytes exhibited decreased levels of CHMP5 protein, as well as lower expression of the CHMP5 target Bcl2 protein. From these data, Adoro et al. 1 proposed a model wherein low-affinity TCR/peptide:MHC interactions signal phosphorylation of CHMP5 to facilitate USP8-CHMP5 interactions that stabilize CHMP5 protein (Figure 1) . In turn, CHMP5 binds to Bcl2 and suppresses Bcl2 degradation, ultimately promoting survival of positively selected thymocytes and further αβ T cell development (Figure 1 ).
This seminal study represents a major advancement in our mechanistic understanding of positive selection and αβ T lymphocyte development. It also raises many substantial questions that should guide future research in this area. For example, it will be critical to identify the TCR signaling pathway and downstream kinase that induces CHMP5 phosphorylation in thymocytes following intrathymic, low-affinity TCR/peptide:MHC interactions. Likewise, it will be important to determine the E3 ubiquitin ligase that modifies CHMP5 and whether TCR signaling inhibits the activity of this enzyme to augment CHMP5 stabilization. Although Adoro et al. 1 favor the model that the binding of CHMP5 to Bcl2 directly impairs the ubiquitylation and resultant degradation of Bcl2, other scenarios warrant investigation. In this context, CHMP5 might recruit additional factors, such as USP8 or another DUB, that stabilize oxidized Bcl2 proteins. Furthermore, the phosphorylation of CHMP5 may independently and directly promote association with Bcl2. It seems likely that CHMP5 would promote survival and continued differentiation of positively selected αβ T cells by promoting the stability of proteins in addition to Bcl2. Moreover, signaling from low-affinity TCR/peptide:MHC interactions may control these processes through post-transcriptional regulation of many proteins beyond CHMP5.
The mechanisms uncovered in this study may also have broad implications for cellular differentiation and function beyond the positive selection of immature αβ T cells. Considering that Chmp5 transcripts are expressed throughout thymocyte development, the selection and further differentiation of cells that have assembled functional TCRβ genes could involve stabilization of CHMP5 by pre-TCR signaling. CHMP5 could similarly direct selection and development of γδ T cells. Although Adoro et al. 1 showed that high-affinity TCR/peptide:MHC interactions signal downregulation of Chmp5 mRNA and CHMP5 protein, the mechanisms and potential function of this regulation in promoting negative selection remains unresolved. As the inactivation of CHMP5 in developing thymocytes blocked the generation of mature αβ T cells, the potential roles of CHMP5 in mediating αβ T-cell effector functions should be investigated. Nevertheless, the findings of Adoro et al. 1 suggest that inherited hypomorphic or somatic mutations of CHMP5 could predispose individuals to diverse immunological disorders. As this study is the second example of a physiologically critical non-canonical function of CHMP5, it seems highly possible that CHMP5, and perhaps other ESCRT proteins, mediate cellular processes beyond membrane biology and endosomal trafficking. Low-affinity interactions between TCR and peptide: MHC stabilizes the ESCRT protein CHMP5 by phosphorylation of serine 26 and 30 by an unidentified kinase. This phosphorylation recruits the deubiquitylating enzyme USP8, which removes ubiquitin moieties at lysine 100. In this manner, CHMP5 is protected from proteasomal degradation. As a result, CHMP5 binds to and stabilizes the anti-apoptotic factor Bcl2, presumably shielding it away from degradative reactive oxygen species.
